Less than 10 years ago, the Sanger sequencing method provided the only technology for DNA sequencing. High throughput sequencing, also referred to as nextgenera tion sequencing, changed the fi eld by addressing limita tions associated with conventional sequencing, such as throughput, scalability and cost. Th e fi rst Personal Genomes meeting, held in 2008, was a forum for discuss ing some of the fi rst personal genomes namely, James Watson's genome, which was sequenced using high throughput sequencing technology. Since then, the Personal Genomes meeting has expanded each year, refl ecting the growing interest in exploiting genome technology to improve the diagnosis and treatment of human disease. Th is year, the fi fth annual meeting refl ected this interest by including pharmacogenomics and updated the meeting title to include medical genomics. Th e meeting covered innovations in the use of genomics for diagnosing Mendelian disorders and cancer and augmenting their treatment, as well as the technical, ethical and policybased implications of transiting genome technology and genomic data in the clinic.
Continued successes and challenges of clinical sequencing
Th e fi rst keynote speaker, Retta Beery (Encinitas, Cali fornia, USA), presented her family's personal journey with twins suff ering from Segawa's dystonia, a progressive muscle disorder that causes muscle spasms and impaired motor control. Th e standard of care (Ldopa supple men ta tion) was not fully eff ective, so, through wholegenome sequencing (WGS) by Baylor College of Medicine's Human Genome Sequencing Center, an improved, personalized treatment plan for the twins was estab lished. Th is resulted in a miraculous improvement in their muscle control and in their quality of life. Beery went so far as to request that the names of the twins be included in publications to personalize the impact of this study, and stressed that her children are outstanding examples of the potential that genomics holds for medicine.
Th is success story, along with the growing number of other genome sequencing case studies, forms a cogent argument for integrating WGS in the clinic. Th is year, speakers shared stories of both the successes and challenges of this transition. For example, Stephen Quake (Stanford University, USA) shared his work on developing a noninvasive, prenatal test for Down syndrome, based on the highthroughput sequencing of fetal cellfree DNA from the whole blood of the mother. Quake pointed out that this is one of the fi rst highthroughput sequen cing tests to transition to the clinic.
Howard Jacob (Medical College of Wisconsin, Children's Hospital of Wisconsin, USA) outlined key challenges in clinical sequencing. While data storage, analysis and clinical certifi cations such as Clinical Labora tory Improvement Amendments (CLIA) or College of American Pathologists (CAP) remain costly challenges, Jacob argued that new challenges his group and others are facing involve reconciling genome analysis with the decisionmaking guidelines of physicians. To this eff ect, Jacob shared the story of a child with early onset, aggressive infl ammatory bowel disease, where conven tional testing rendered no clear diagnosis. Sequen cing the child's genome revealed a rare variant in Xlinked inhibitor of apoptosis (XIAP), and previous literature had connected XIAP to the infl ammatory res ponse and to the nucleotidebinding oligomerization domain (NOD) signal ing pathway. However, to convince the physician to make a diagnosis and initiate treatment, further assays and experimental support were required. Convinced by this additional experimental evidence, the physician made the diagnosis and ordered a bone marrow transplant of cord blood cells. Th e patient recovered, and three years later has not experienced a recurrence of symptoms.
Benchmarking the performance of clinical exomes
Not all sequencing data result in clear, actionable infor mation, as Jacob and other speakers point out. Certain portions of the genome are inherently inaccessible to some platforms and sequencing applications. Even when it is possible to detect genome variants, this does not necessarily lead to a change in treatment. Many speakers argued for exome sequencing, which is costeffective and offers a similar or even better rate of actionable diagnoses compared with WGS. Sharon Plon (Baylor College of Medicine, USA) described the oneyear status of clinical exome sequencing performed by Baylor College of Medicine's Whole Genome Laboratory (WGL), which also includes the mitochondrial genome. The WGL performs several quality control steps, as well as a consultation with a signout team of American Board of Medical Geneticscertified lab directors, medical direc tors, clinicians and genetic counselors, before releasing a twopart report on discovered exome variants. First, the focused variant report, which describes variants of known and unknown significance found in genes related to the reported disease or clinical phenotypes, is created and delivered directly to the requesting physician. A second, optional variant report is available upon request, and contains additional variants with no direct connec tion to the reported disease, or to clinical phenotypes. This clinical service has been applied to hundreds of exomes of which 85% are from pediatric patients with a successful diagnostic rate of about 25%. The majority of exomes sequenced at the WGL are ordered by physicians for patients suffering from neurological phenotypes, for whom conventional genetic testing has yielded no insights.
Han Brunner (University Medical Center Nijmegen, the Netherlands) reported a similar success rate for diagnostic exome sequencing, and, like the WGL, he reported that the greatest portion of patients suffered from neurological disorders. Brunner also noted success ful diagnoses even in disorders with only a single de novo mutation. For example, in two boys exhibiting nearly identical craniofacial phenotypes, Brunner found a common de novo mutation using exome sequencing. This phosphofurin acidic cluster sorting protein 1 (PACS1) mutation was then engineered into an animal model, and its causative relationship with the phenotype was verified. Lisenka Vissers (University Medical Center Nijmegen, Nether lands) also discussed the utility of exome sequen cing in identifying de novo mutations in the majority of diagnosed intellectual disorders.
Developing standards for analysis and interpretation
There are several highthroughput sequencing platforms, with many emerging applications for sequencing. These platforms and applications offer different tradeoffs of cost, speed, throughput, read lengths, error rates and bias. Ultimately, as these technologies mature, sequence analysis will be more straightforward, but in the mean time analysis remains a challenge and bottleneck.
Michael Eberle (Illumina, San Diego, USA) discussed the Illumina's Platinum Genome project, which aims to provide a gold standard set of genomes and variant calls for use in benchmarking sequence analysis tools. As Eberle explained, variant callers are often benchmarked by testing the Mendelian consistency of calls within a parentoffspring trio; however, this consistency test captures only a subset of genotyping error. Illumina has sequenced an extended family, leveraging a multi genera tional pedigree to create a high quality set of whole genome variant calls for the highly characterized CEPH/ Utah Pedigree 1463. Eberle reports that for single nucleotide polymorphisms (SNPs), the set of variants is more than 99.9998% accurate. As supporting data are gathered for every variant, the Platinum Genomes project will publicly release and curate the dataset.
There are also problems with variant calling that are rooted in short read sequencing technology, as Jay Shendure (University of Washington, USA) points out. Shendure proposes haplotype phasing as a means to improve variant calls. His method for a haplotype resolved genome combines highthroughput sequencing with assemblies of barcoded fosmid libraries, each con tain ing a small portion of the diploid genome.
The importance of ethnically diverse reference resources was also discussed at the meeting. For example, Jun Yang (St Jude Children Research Hospital, USA) found that racial differences among pediatric patients with acute lymphoblastic leukemia significantly affected suscepti bility and outcome. Yang's study, involving more than 2,000 children with acute lymphoblastic leukemia, identified multiple treatmentaffecting variants both specific and common to their different human sub populations.
Defining guidelines for sharing genomic data
Anita Allen (Presidential Commission for the Study of Bioethical Issues (PCSBI), USA), described suggestions by the PCSBI for ensuring the ongoing privacy and security of data in the rapidly developing field of high throughput sequencing. Allen stressed that although many variants are of unknown significance today, future discoveries may illuminate their significance. Therefore, it is important to develop policies to define how and when to share genetic information, even if it is not immediately actionable. Arthur Beaudet (Baylor College of Medicine, USA) also offered a perspective, as part of the ethics panel, on genetic counseling in prenatal diag nostics. Beaudet cites the Ashkenazi Jewish community as among the most progressive adopters of prenatal diagnostics, in spite of their sensitivity to genocide and eugenics. Gholson Lyon (Cold Spring Harbor Laboratory, USA) highlighted the need for improved variant calling and interpretation. In one example, he showed the dis agreement of variant callers using a telling Venn diagram, referring to it as the threering circus. With regard to interpretation, Lyon pointed out challenges beyond improved annotation of variants namely, penetrance and variable expressivity. The effect of variants on phenotype depends on the genetic back ground, and for this reason he argues for the analysis and interpretation of variants using extended families.
The final keynote lecture was delivered by Maynard Olson (University of Washington, USA), who urged the group to consider the term 'precision medicine' in place of 'personalized medicine' . The rationale is that high throughput sequencing is enabling the precise diagnosis and treatment of disease. Olson further challenged genome scientists and institutions to focus on even larger scale populations to aid in the discovery of rare variants. Data sharing is also critical for advancement, Olson argued, and his idea for data sharing involved a large databank of anonymized, publicly shared data from which everyone may derive insight. The term 'precision medicine' was a hit at the meeting and is incorporated in the title for the upcoming 2013 meeting, 'Precision Medicine: Personal Genomes and Pharmacogenomics' .
Conclusions
Improvements in highthroughput sequencing techno lo gies have made sequencing personal genomes feasible.
Case studies presented at the Personal Genomes and Medical Genomics meeting continue to demonstrate that clinical sequencing can be a powerful tool for the diagnosis and treatment of a variety of human diseases. However, challenges remain in fully characterizing variation in human genomes. Some of these challenges will resolve as sequencing technologies mature and analysis standards are better defined. As we commoditize the analysis of personal genomes, new challenges will center on interpreting the clinical impact of genomic data within the context of clan genomics, molecular patient profiles, medical records, and the scientific literature.
